Analysts Anticipate Gemphire Therapeutics Inc (GEMP) to Post -$0.45 EPS

Wall Street brokerages predict that Gemphire Therapeutics Inc (NASDAQ:GEMP) will report earnings per share (EPS) of ($0.45) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Gemphire Therapeutics’ earnings, with estimates ranging from ($0.48) to ($0.41). Gemphire Therapeutics posted earnings per share of ($0.82) during the same quarter last year, which would suggest a positive year-over-year growth rate of 45.1%. The company is scheduled to issue its next earnings results on Monday, November 12th.

According to Zacks, analysts expect that Gemphire Therapeutics will report full year earnings of ($1.88) per share for the current year, with EPS estimates ranging from ($1.89) to ($1.86). For the next year, analysts expect that the company will post earnings of ($2.05) per share, with EPS estimates ranging from ($2.50) to ($1.59). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Gemphire Therapeutics.

Gemphire Therapeutics (NASDAQ:GEMP) last issued its earnings results on Monday, August 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.05.

A number of equities analysts have issued reports on GEMP shares. Roth Capital raised their target price on Gemphire Therapeutics from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, July 27th. Canaccord Genuity restated a “buy” rating and set a $6.00 target price on shares of Gemphire Therapeutics in a report on Monday, August 13th. Zacks Investment Research upgraded Gemphire Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a report on Tuesday, August 14th. Jefferies Financial Group cut Gemphire Therapeutics from a “buy” rating to a “hold” rating and set a $15.00 target price on the stock. in a report on Monday, August 13th. Finally, ValuEngine upgraded Gemphire Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 5th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $17.82.

GEMP traded down $0.01 during midday trading on Friday, reaching $1.77. 101,753 shares of the company were exchanged, compared to its average volume of 480,611. The company has a current ratio of 4.64, a quick ratio of 4.64 and a debt-to-equity ratio of 0.50. Gemphire Therapeutics has a one year low of $0.83 and a one year high of $11.43. The stock has a market cap of $29.39 million, a P/E ratio of -0.55 and a beta of 0.90.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Segall Bryant & Hamill LLC raised its position in shares of Gemphire Therapeutics by 100.0% during the first quarter. Segall Bryant & Hamill LLC now owns 30,000 shares of the company’s stock worth $195,000 after purchasing an additional 15,000 shares during the period. Northern Trust Corp raised its position in shares of Gemphire Therapeutics by 63.7% during the first quarter. Northern Trust Corp now owns 30,080 shares of the company’s stock worth $196,000 after purchasing an additional 11,708 shares during the period. JBF Capital Inc. acquired a new stake in shares of Gemphire Therapeutics during the second quarter worth about $204,000. Acadian Asset Management LLC acquired a new stake in shares of Gemphire Therapeutics during the second quarter worth about $286,000. Finally, Nomura Holdings Inc. acquired a new stake in shares of Gemphire Therapeutics during the second quarter worth about $556,000. 32.60% of the stock is currently owned by institutional investors.

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.

Featured Article: Does the discount rate affect the economy?

Get a free copy of the Zacks research report on Gemphire Therapeutics (GEMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply